Video: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You

“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up to a location just a few miles from here to show you Elon Musk’s next AI product. I promise what happens next will shock you…”

R Sanders Williams net worth and biography

R Williams Biography and Net Worth

Director of Amgen

R. Sanders Williams is the President Emeritus of Gladstone Institutes, a non-profit biomedical research enterprise, having served in this position since 2018, and was the Chief Executive Officer of Gladstone Foundation, a not-for-profit organization supporting the Gladstone Institutes during 2018. Dr. Williams has served as Professor of Medicine at Duke University since 2018 and, beginning in January 2021, is acting as Interim Vice President for Research and Innovation. He has been a Professor of Medicine at the University of California, San Francisco since 2010. Dr. Williams was both President of Gladstone Institutes and its Robert W. and Linda L. Mahley Distinguished Professor of Medicine, from 2010 to 2017. Prior to this, Dr. Williams served as Senior Vice Chancellor of the Duke University School of Medicine from 2008 to 2010 and Dean of the Duke University School of Medicine from 2001 to 2008. He was the founding Dean of the Duke-NUS Graduate Medical School, Singapore, from 2003 to 2008 and served on its Governing Board from 2003 to 2010. From 1990 to 2001, Dr. Williams was Chief of Cardiology and Director of the Ryburn Center for Molecular Cardiology at the University of Texas, Southwestern Medical Center.

Dr. Williams has been a director of the Laboratory Corporation of America Holdings, a diagnostic technologies company, since 2007, serving on the Audit Committee and chairing the Quality and Compliance Committee. Dr. Williams was a director of Bristol-Myers Squibb Company, a pharmaceutical company, from 2006 until 2013. Dr. Williams has served on the board of directors of the Gladstone Foundation, a non-profit institution that is distinct from Gladstone Institutes, since 2012. Dr. Williams was elected to the National Academy of Medicine in 2002. Dr. Williams received his undergraduate degree from Princeton University and his doctorate from Duke University.

What is R Sanders Williams' net worth?: The estimated net worth of R Sanders Williams is at least $1.48 million as of August 22nd, 2022. Dr. Williams owns 5,301 shares of Amgen stock worth more than $1,483,008 as of December 3rd. This net worth evaluation does not reflect any other assets that Dr. Williams may own. Learn More about R Sanders Williams' net worth.
How do I contact R Sanders Williams?: The corporate mailing address for Dr. Williams and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on R Sanders Williams' contact information.
Has R Sanders Williams been buying or selling shares of Amgen?: R Sanders Williams has not been actively trading shares of Amgen within the last three months. Most recently, R Sanders Williams sold 200 shares of the business's stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $249.96, for a transaction totalling $49,992.00. Following the completion of the sale, the director now directly owns 5,301 shares of the company's stock, valued at $1,325,037.96. Learn More on R Sanders Williams' trading history.
Who are Amgen's active insiders?: Amgen's insider roster includes Robert Bradway (Chairman & Chief Executive Officer), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.
Are insiders buying or selling shares of Amgen?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 4,213 shares worth more than $1,235,082.41. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.
Information on this page was last updated on 5/3/2024.

R Sanders Williams Insider Trading History at Amgen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2022	Sell	200	$249.96	$49,992.00	5,301
5/23/2022	Sell	600	$250.00	$150,000.00	5,501
5/7/2021	Sell	250	$251.78	$62,945.00	4,409
2/8/2021	Sell	250	$237.99	$59,497.50	4,659
11/9/2020	Sell	250	$242.40	$60,600.00	4,909
8/7/2020	Sell	250	$242.95	$60,737.50	5,159
5/6/2020	Sell	425	$237.31	$100,856.75	5,834
2/6/2020	Sell	425	$233.72	$99,331.00	4,988
11/6/2019	Sell	425	$215.45	$91,566.25	5,413
8/7/2019	Sell	425	$183.04	$77,792.00	16,336

R Sanders Williams Buying and Selling Activity at Amgen

Amgen Company Overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Today's Range

Now: $279.76

$276.50

$280.42

50 Day Range

MA: $311.37

$278.76

$335.61

2 Week Range

Now: $279.76

$257.80

$346.85

Volume

1,378,881 shs

Average Volume

2,571,082 shs

Market Capitalization

$150.38 billion

P/E Ratio

35.82

Dividend Yield

3.18%

Beta

0.55

This company will win the AI race

From Porter & Company | Ad

Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.